Best’s Insurance Law Podcast: Understanding the Impact of Wrongful Expert Designation

OLDWICK, N.J.--(BUSINESS WIRE)-- AM Best and Best’s Insurance Professional Resources have released the latest installment of the Best's Insurance Law Podcast series, which examines timely insurance issues from a legal perspective.

This episode discusses what happens when an expert service provider is designated on a case without having provided consent and the impact that has on cases.

The podcast features Dr. Janine McCartney from expert service provider HHC Safety Engineering Services, Inc. Dr. McCartney is a certified safety professional (CSP), construction health and safety technician (CHST) and registered professional industrial hygienist (RPIH). She has over 25 years’ experience working as an expert.

HHC Safety Engineering Services, Inc., is a qualified member of Best's Insurance Professional Resources, an insurance industry resource that has featured qualified legal counsel, independent insurance adjusting services and expert service providers since 1929.

Listen or subscribe to Best’s Insurance Law Podcast.

AM Best is a global credit rating agency, news publisher and data analytics provider specializing in the insurance industry. Headquartered in the United States, the company does business in over 100 countries with regional offices in London, Amsterdam, Dubai, Hong Kong, Singapore and Mexico City. For more information, visit www.ambest.com.

Copyright © 2022 by A.M. Best Company, Inc. and/or its affiliates. ALL RIGHTS RESERVED.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220428006020/en/

Christopher Sharkey
Manager, Public Relations
+1 908 439 2200, ext. 5159
[email protected]

Jeff Mango
Managing Director, Strategy & Communications
+1 908 439 2200, ext. 5204
[email protected]

Source: AM Best

You May Also Be Interested In

• Cinemo, Dolby, and SmashLabs Bring In-Car Immersive Gaming Experiences to the Next Level
• Ibogaine By David Dardashti Releases Unprecedented Clinical Footage of Full Treatment Protocol Amid Federal Push for Psychedelic Therapy
• Leads Biolabs' Opamtistomig (PD-L1/4-1BB Bispecific Antibody) NDA Accepted by NMPA, Poised to Become World's First Approved 4-1BB-Targeting Therapy